Pharmacogenomic Study (Adjuvant Chemotherapy)

Completed

• Conditions: Gastric Cancer

• Registration Number: NCT01470404
• Lead Sponsor: Samsung Medical Center

Brief Summary

To assess the role of germline polymorphisms in xenobiotic metabolism genes in toxicity profile.

To assess the role of germline polymorphisms in genes associated with DNA repair, p53 tumor suppressor gene and angiogenesis pathway in predicting recurrence and survival in gastric cancer patients treated with adjuvant chemotherapy.

Detailed Description

Not available

Study Timeline

• Study Start: 2008-07-10
• Study First Submitted: 2011-11-09
• Study First Submitted QC: 2011-11-10
• Study First Posted: 2011-11-11
• Primary Completion: 2013-05-10
• Study Completion: 2013-07-10
• Status Verified: 2018-01
• Last Update Submitted: 2018-01-15
• Last Update Posted: 2018-01-17

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 792

Inclusion Criteria

• gastric cancer patients treated with adjuvant chemotherapy

Exclusion Criteria

Not provided

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
germline polymorphisms in xenobiotic metabolism genes in toxicity profile	36 months

Trial Locations

Locations (1)

Samsung Medical Center; 🇰🇷 Seoul, Korea, Republic of